Infectious Disease Clinical Trials 2024

What are the top hospitals conducting infectious disease research?

When it comes to tackling infectious diseases, several hospitals are at the forefront of cutting-edge research and clinical trials. A notable player in this field is the National Institutes of Health Clinical Center located in Bethesda. With two ongoing infectious disease trials and an impressive track record of 39 completed studies since their inaugural trial in 1978, this renowned institution has been instrumental in advancing our understanding and treatment options for various infectious diseases.

Another esteemed hospital making strides in infectious disease research is the University of Maryland based in Baltimore. While they currently have one active clinical trial focused on infectious diseases, their contribution extends beyond that with nine previously conducted studies dating back to 1997. This institution's dedication to exploring new treatments and preventive measures plays a crucial role in combatting these persistent health threats.

In addition to these well-established hospitals, newer players are emerging on the scene as key contributors to combating infectious diseases through clinical trials. Cullman Clinical Trials, located in Cullman, joins this league with one ongoing trial dedicated specifically to studying infectious diseases. Although they have only recently entered the arena of medical research with their first recorded trial occurring in 2023, their commitment signifies a rising interest among healthcare providers towards addressing urgent public health challenges.

Similarly committed is Lifeline Primary Care situated in Lilburn along with Georgia Clinic located Norcross; both institutions have also initiated one active clinical trial each focusing solely on battling different types of infectious diseases from early stages starting from same year as mentioned above i.e.,2023 These newcomers demonstrate that even smaller-scale facilities can play a significant role by dedicating resources and expertise towards expanding our knowledge about these complex illnesses.

Through the collective efforts of these leading institutions across regions, we witness an unwavering determination to conquer infectious diseases through rigorous scientific investigation. Such groundbreaking endeavors aim not just at improving individual lives affected by such conditions but also contribute significantly towards safeguarding global public health for generations yet unborn

Which are the best cities for infectious disease clinical trials?

When it comes to infectious disease clinical trials, certain cities stand out as hubs for research and development. Bethesda in Maryland has 3 active trials investigating treatments like Treatment Arm and Arm 1. Baltimore, also in Maryland, follows closely with 2 ongoing studies focusing on Attachment and Biobehavioral Catch-up (ABC) program, as well as Prospective audit-and-feedback. Salt Lake City in Utah and Boston in Massachusetts both have 2 active trials each exploring various interventions such as Vancomycin and Tobramycin, Health Information Exchange (HIE) platform, vitamin d + fish oil. Lastly, Cullman in Alabama has 1 active trial underway examining different treatment arms. These cities play a vital role in advancing our understanding of infectious diseases through their participation in cutting-edge clinical trials.

Which are the top treatments for infectious disease being explored in clinical trials?

Clinical trials are constantly pushing the boundaries in the search for effective treatments against infectious diseases. Among the top contenders currently being explored are:

• Darunavir: A potent antiviral drug with 9 active clinical trials and a notable track record of 567 all-time infectious disease trials since its debut.
• Remdesivir: Gaining attention for its potential efficacy against multiple viral pathogens, remdesivir is involved in 6 ongoing infectious disease studies and has amassed an impressive tally of 256 all-time clinical trials.
• Azithromycin: Widely used to combat bacterial infections, azithromycin remains under scrutiny with involvement in 5 active clinical trials focused on various infectious diseases.

These promising treatments hold great promise as researchers strive towards finding more effective ways to tackle the challenges posed by infectious diseases.

What are the most recent clinical trials for infectious disease?

In the field of infectious disease, significant advancements are being made through recent clinical trials. One such trial is Arm 1, which has reached Phase 2 and became available on 8/2/2023. Group A is another noteworthy study in Phase 1 that became accessible on 6/15/2023. Additionally, Arm A's Phase 2 trial was initiated on 6/7/2023, offering potential insights into combating infectious diseases. These trials exemplify the ongoing efforts to develop effective treatments for infectious diseases and signify a promising future in this crucial area of healthcare research.

What infectious disease clinical trials were recently completed?

Promising advancements in the field of infectious disease research have been made through several recently completed clinical trials. These include a trial sponsored by Tonix Pharmaceuticals, Inc., which investigated TNX-102 SL and reached completion in August 2022. Seqirus also conducted an impactful trial focused on aH5N6c on Day 22, concluding in July 2022. Furthermore, Novartis Pharmaceuticals successfully completed a trial exploring Cryptosporidium parvum oocysts (ABO809) treatment options in April 2022. These milestones reflect the dedication of researchers working tirelessly to combat infectious diseases and offer hope for improved treatments for patients worldwide.